title: Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
abstract: The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.
authors.affiliation: *Graduate School of Medicine †Department of Internal Medicine, Division of Hematology and Oncology, University of Tennessee, Knoxville, TN.
authors.forename: Harsha A
authors.initials: HA
authors.lastname: Ranganath
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Panella
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D016031:Liver Transplantation / Q000009:adverse effects; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; D000074324:Ipilimumab